文献速递核素与放射性配体治疗骨显像与常规 SPECT

177Lu-前列腺特异性膜抗原超级扫描及放射性配体治疗1周期后良好应答

177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy.
PubMed 文献 · Clin Nucl Med · 2018-01-01

一例76岁去势抵抗性前列腺癌伴广泛骨转移患者接受2周期177Lu-PSMA-617治疗。第1周期后全身扫描示弥漫骨PSMA高摄取而肾无摄取、唾液腺摄取极低(超级扫描);6周后第2剂治疗后扫描示骨转移显著消退,肾与唾液腺PSMA摄取恢复正常。作者称这是首例Lu-PSMA超级扫描病例报告。

要点

  • 177Lu-PSMA治疗后全身扫描可表现为弥漫骨高摄取而肾及唾液腺摄取缺失的超级扫描。
  • 该患者第2剂治疗后骨转移显著消退,肾与唾液腺PSMA摄取恢复正常。
  • 作者称这是首例Lu-PSMA超级扫描的病例报告。

核心结论

  • 作者称这是首例Lu-PSMA超级扫描的病例报告。

研究设计与样本

  • 病例报告:76岁去势抵抗性前列腺癌伴广泛骨转移男性,在本院接受2周期177Lu-PSMA-617治疗。

主要发现

  • 第1周期后全身177Lu-PSMA扫描示弥漫骨PSMA高摄取病灶,而肾未见PSMA摄取,唾液腺PSMA摄取极低(超级扫描)。
  • 6周后接受第2剂177Lu-PSMA,治疗后全身扫描示骨转移显著消退,肾与唾液腺PSMA摄取恢复正常。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 76-year-old man with castration-resistant prostate cancer and widespread skeletal metastases underwent 2 cycles of Lu-prostate-specific membrane antigen (PSMA) 617 therapy in our department. Whole-body Lu-PSMA scan after the first cycle showed diffuse skeletal PSMA-avid lesions, whereas no PSMA uptake was evident in the kidneys with minimal PSMA uptake by salivary glands (super scan). After 6 weeks, he received the second dose of Lu-PSMA and whole-body scan after the treatment showed remarkable resolution of skeletal metastases and normal PSMA uptake by the kidneys and salivary glands. To our best knowledge, this is the first case report of Lu-PSMA super scan.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Aryana K, Zarehparvar Moghadam S, Salek R, et al. 177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy. Clin Nucl Med. 2018. PMID: 29401146. doi:10.1097/RLU.0000000000001986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。